



#9  
YC  
8-13-02

COPY OF PAPERS  
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd RIEDL et al.

Serial No.: 09/777,920

Filed: February 7, 2001

Examiner: Desai, Rita J.

Group Art Unit: 1625

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

Title: INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR  
PYRIDYL UREAS

**REPLY UNDER 37 CFR §1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I hereby certify that this correspondence is being deposited  
with the U.S. Postal Services as First Class Mail in an envelope  
addressed To: Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 On: 7/15/2002  
Name: Richard J. Trams  
Signature: [Signature]  
Date: 7/15/2002

In response to the office action dated January 15, 2002, please consider the remarks  
below:

**REMARKS**

**Election/Restriction**

Applicants affirm their election of Group I and maintain their traverse of the restriction requirement. It has not been shown that examination of the full scope of the claims would be an undue burden. The compounds of formula I have the moiety "B" defined as substituted and unsubstituted quinoline, isoquinoline or pyridinyl groups. Claims to such compounds clearly have a common nucleus. It has not been shown how the substituents on A and B, such as R<sub>x</sub>, R<sub>f</sub> and R<sub>z</sub> would require separate searches. The substituents on B do not change its identity as a substituted quinoline, isoquinoline or pyridinyl group. Therefore, Applicants maintain that examination of the full scope of claims 1-33, with all of the variations for R<sub>x</sub>, R<sub>z</sub> and R<sub>f</sub> would not be an undue burden.

**Claim Objections**

The objection to claims 31-33 as containing figures is not understood. These claims